CFB
ACAD icon

Cullen/Frost Bankers’s Acadia Pharmaceuticals ACAD Stock Holding History

Cullen/Frost Bankers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.56K Hold
70
– – ﹤0.01% 1276
2025
Q4 		$1.87K Hold
70
– – ﹤0.01% 1260
2025
Q3 		$1.49K Hold
70
– – ﹤0.01% 1244
2025
Q2 		$1.51K Hold
70
– – ﹤0.01% 1207
2025
Q1 		$1.16K Buy
+70
New +$1.27K ﹤0.01% 1213

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Cullen/Frost Bankers's ACAD Position: Q1 2026 in Review

Cullen/Frost Bankers held its Acadia Pharmaceuticals (ACAD) position steady in Q1 2026 at 70 shares worth $1.56K. The position accounts for ﹤0.01% of the portfolio, ranked #1276.

Cullen/Frost Bankers first reported a position in ACAD in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.87K in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Cullen/Frost Bankers held 70 shares of Acadia Pharmaceuticals worth $1.56K as of Q1 2026.
  • Cullen/Frost Bankers left its Acadia Pharmaceuticals share count unchanged in Q1 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q1 2026, its #1276 holding.
  • Cullen/Frost Bankers first reported a position in Acadia Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Cullen/Frost Bankers's Acadia Pharmaceuticals position peaked at $1.87K in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.